About MeI’m an oncologist treating patients with leukemia and other blood cancers. I have a pharmacology background and a specialized research focus in experimental chemotherapy and drug development. I serve as Chairman and Professor in the Department of Internal Medicine and hold the Bertha Bouroncle MD and Andrew Pereny Chair in Medicine.
At the OSUCCC – James, we use the latest technologies in our search for more effective and targeted cancer treatments, then apply our findings to patient care as quickly and responsibility as possible. As a physician and scientist, I have more than 30 years experience in the research and development of therapies for patients with hairy cell leukemia, CLL (chronic lymphocytic leukemia) and other hematologic malignancies. I serve as principal investigator on the NCI-funded Phase I / II clinical trial grant.
My work has been published in medical journals, including Molecular Cancer Therapeutics, Blood, and Journal of Clinical Oncology. I've also been honored with a number of awards, including Best Doctors in America, the Distinguished Alumnus Award from University of Pittsburgh and more recently the The Ohio State University Distinguished Scholar Award.
- Named to the Castle Connolly list of America’s “Top Doctors” for 2017
- Best Doctor in America 2017
Specialties and conditions I treat
- Hairy Cell Leukemia
- Blood Cancers
Locations where I practice
Education and training
University of Pittsburgh School of Medicine
University of Pittsburgh Medical Center Presbyterian
7/1/1972 - 6/30/1974
More about my work
Ohio State University Wexner Medical Center
7/1/1976 - 6/30/1978
American Board of Internal Medicine
American Board of Internal Medicine (Subspecialty: Hematology)
American Board of Internal Medicine (Subspecialty: Medicine Oncology)
News about me
- John C. Byrd Awarded Prestigious 2015 William Dameshek Prize
- Ohio State Hematologist Recognized Nationally With Top 10 Clinical Research Achievement Award
- Ohio State And Malaysia Centre Join Forces In The Global Fight Against Cancer, Develop Possible Anticancer Drug
- Targeted Agent Selumetinib Shows Promise In Biliary Cancer
- Second Ohio State Cancer Drug Begins Clinical Trials Testing
- Ohio State Announces Director Of New Medical Oncology Division
Consulting and Related Relationships
At The Ohio State University Wexner Medical Center, we support a faculty member’s research and consulting in collaboration with medical device, research and/or drug companies because a faculty member’s expertise can guide important advancements in the practice of medicine and improve patient care. In order to provide effective management of these relationships, the University requires annual disclosures from all faculty members with external interests related to their University responsibilities.
As of 03/28/2017, Dr. Grever has reported financial relationships with the medical device, research and/or drug companies listed below. If you have questions about the relationships listed below, please ask the faculty member. If you have questions about how these relationships are monitored by The Ohio State University Wexner Medical Center, please contact our Compliance Office at 614-293-7802.
- Pharmacyclics, Inc.